Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Obicetrapib in ASCVD / HeFH (LDL-C efficacy). The expected timing is based on the latest available company guidance and may change.
BROADWAY trial. 12/10/24- Topline data reported. 5/7/25- New data at EAS'25. Additional data in 2025. 11/05/25:- Pooled BROADWAY/BROOKLYN MACE analysis published in JACC; additional LDL particle data at AHA 2025. 02/18/26:- Additional BROADWAY LDL-C data planned in 2026; EMA/UK/Swiss approval decisions for obicetrapib expected H2 2026. 03/23/26:- BROADWAY kidney-function poster at ACC.26 on March 28, 2026. Additional pooled safety poster March 29. 05/07/26:- ACC BROADWAY/BROOKLYN analyses showed renal benefits; more data through 2026; EMA/UK/Swiss approvals H2 2026; launches Q4 2026. 06/03/26:- Integrated Ph3 safety, pooled MACE, and BROADWAY kidney-function results at NLA 2026 June 12. 07/24/26:- CHMP recommended Ubeslo EU marketing authorization. European Commission decision expected H2 2026. 08/05/26:- NLA analyses showed pooled MACE reduction; more BROADWAY data expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.